FDA Expands Use of First CAR T-cell Therapy to Non-Hodgkin Lymphoma
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
Last week, the U.S. Food and Drug Administration (FDA) approved the antihormone agent apalutamide (Erleada) for treating men with...
The field of medical oncology is undergoing a remarkable transformation. Cancers that were once considered death sentences, such as...
The U.S. Food and Drug Administration (FDA) recently added a new therapeutic to the armamentarium for oncologists treating patients...
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...
A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the antibody–drug conjugate brentuximab vedotin (Adcetris)...
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...